31

Results
32
The 89 Zr-DFO radiolabeling efficiency of Jurkat/CAR and human peripheral blood 33 mononuclear cells (hPBMC)/CAR T-cells was 70-79%, and cell radiolabeling activity was 98. 1-103.6 34 kBq/10 6 cells. Cell viability after radiolabeling was >95%. Compared with unlabeled cells, cell 35 proliferation was not significantly different during the early period after injection; however, the 36 proliferative capacity decreased over time (p = 0.02, day 7 after labeling). IL-2 or IFN- secretion was 37 not significantly different between unlabeled and labeled CAR T-cells. PET/magnetic resonance images 38 in the xenograft model showed that most of the 89 Zr-DFO-labeled Jurkat/CAR T-cells were distributed 39 in the lung (24.4%  3.4%ID) and liver (22.9%  5.6%ID) by 1 hour after injection. The cells gradually 40 migrated from lung to the liver and spleen by day 1, and remained stably until day 7 (on day 7: lung 41 3.9%  0.3%ID, liver 36.4%  2.7%ID, spleen 1.4%  0.3%ID). No significant accumulation of labeled 42 cells was identified in tumors. A similar pattern was observed in ex vivo biodistributions on day 7 (lung 43 3.0%  1.0%ID, liver 19.8%  2.2%ID, spleen 2.3%  1.7%ID). 89 
70
Unfortunately, none of these can monitor CAR T-cells within a live body. To optimize the efficacy of 71 CAR T-cell immunotherapy and to predict potential toxicities, it is necessary to develop a noninvasive 72 imaging system that can enable the monitoring of CAR T-cell trafficking in a real-time manner. Image-73 based data provides a great deal of information concerning actual tracking, targeting patterns, real-time 74 distributions, and in vivo maintenance for CAR T-cell therapies.
75
Additionally, the FDA Guidance for Industry: Preclinical Assessment of Investigational Cellular and 76 Gene Therapy Products (updated 11/2013) acknowledged that the fate of investigational cell therapy, 77 after in vivo administration is important for characterizing the product's activity and safety information.
78
To determine distribution after cell administration, imaging methods such as radioisotope-labeled cells, 5 79 genetically engineered cells (e.g., green fluorescent protein expression), and nanoparticle-labeled cells 80 (e.g., iron-dextran nanoparticles) are recommended. Unlike conventional drugs, cell therapies must 81 acquire data through in vitro experiments to determine pharmacological activities or unrecognized 82 toxicity. Therefore, animal models are generally recommended for evaluating cell therapies because 83 basic information on the initial behavior, organ distribution, and targeting in the body after cell therapy 
Construction of a lentiviral vector containing CD19-specific CAR
124
To construct a lentiviral vector encoding CAR specific to CD19, we generated EF1α 
211
Before PET image acquisition, the mice were kept under anesthesia (1.5% isoflurane in 100% O 2 gas).
212
Imaging was performed on days 0 (1 hour after the injection), 1, 2, 5, 6 and 7. The 
DFO-labeled Jurkat/CAR T-cells and CAR T-cells 282
The 89 Zr-DFO labeling efficiency of Jurkat/CAR T-cells was 72.8% ± 11.0% at 185 kBq (Fig 3a) .
283
Cell viability after 89 Zr-DFO labeling was 95.2% ± 1.2%, similar to levels obtained before labeling. The 
288
We checked cell viability and cell proliferative ability at 1 hour, day 1, day 3 and day 7 after 89 Zr-289 DFO cell labeling. There was no statistically significant difference in cell viability, although viability 290 decreased over time after cell labeling (p = 0.24, 1 hour: 92.6% ± 3.1%, day 1: 89.4% ± 4.4%, day 3: 291 85.7% ± 8.1%, day 7: 89.0% ± 4.9%, respectively) (Fig 3b) . However, the 89 Zr-DFO-labeled cells 292 showed decreased proliferative ability in a time-dependent manner (Fig 3c) . At 1 hour after cell labeling, 293 cell proliferation ability was not significantly changed, compared with unlabeled cells (p = 0.25). were initially located in the lungs, then redistributed to the liver and spleen (Fig 5a) . In more detail, the 328 injected 89 Zr-DFO-labeled Jurkat/CAR T-cells were found mainly in the lung (24.4%  3.4%ID) and 329 liver (22.9%  5.6%ID) during the first 1 hour. Over time, the CAR T-cells gradually migrated from 330 the lungs and accumulated mainly in the liver, some in spleen (Fig 5b) . However, radioactivity 331 accumulation was not evident in either CD19-positive Raji or CD19-negative K562 tumors. The
332
detailed quantitative values of the PET images analyzed by SUV are shown in Table 1 . Immediately 333 after PET/MR imaging on day 7, the mice were sacrificed, then their organs and tumors were isolated 334 to measure the radioactivity of injected cells ex vivo. Biodistribution data measured ex vivo on day 7 335 showed similar patterns of distribution assessed by PET images as shown in Fig 5c and Flow cytometry, Alu PCR and immunohistochemistry for ex 365 vivo organ study 366 We evaluated biodistribution after injection of unlabeled Jurkat/CAR T-cells using non-imaging 367 methods, for the comparison with using imaging method. For flow cytometry, the liver and spleen tissue 368 samples from mice were separated into single cells. After the initial separation an average number of 369 3.05 × 10 7 and 1.67 × 10 6 cells per mouse were harvested. After depletion of mouse liver cells, an
